# A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

> **NCT05394805** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 156 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05394805
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2024-12-26
- **Final completion:** 2024-12-26
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394805, "A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05394805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*